Impedimed Limited (IPDQF) was downgraded to a Hold Rating at Morgans

In a report released yesterday, Scott Power from Morgans downgraded Impedimed Limited (IPDQFResearch Report) to a Hold, with a price target of A$0.19. The company’s shares closed last Wednesday at $0.13.

According to TipRanks, Power is an analyst with an average return of -1.3% and a 38.60% success rate.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Impedimed Limited with a $0.13 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $0.13 and a one-year low of $0.03. Currently, Impedimed Limited has an average volume of 101.3K.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IPDQF in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. It operates through the Medical, and Test and Measurement segments. The Medical segment supplies non-invasive medical technology products and services to measure, monitor, and manage tissue composition and fluid status using bioimpedance spectroscopy. The Test and Measurement segment offers power precision testing and measuring equipment. The company was founded by Melvyn John Bridges and Lucille Mayse Bridges on September 27, 1999 and is headquartered in Pinkenba, Australia.


(Visited 1 times, 1 visits today)